Nexalin Technology (NXL) announced the appointment of Dr. Robert Rothstein to its Scientific Advisory Board. In anticipation of the Company’s new FDA submissions, Dr. Rothstein will support Nexalin’s preparation of its Q-submission for a meeting with the FDA later this year. Dr. Rothstein has served in senior roles at prestigious institutions including the University of Chicago, Harbor/UCLA Medical Center, and Suburban Hospital/Johns Hopkins Medicine.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXL:
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- 3 Penny Stocks to Watch Now, 10/9/25
- Why Is Nexalin Technology Stock (NXL) Down 20% Today?
- Nexalin Technology announces additional results in AD with Gen-2 SYNC device
- Nexalin Technology announces issuance of U.S. patent covering HALO Clarity